Malignancies Clinical Trials

1 recruiting

Malignancies Trials at a Glance

182 actively recruiting trials for malignancies are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 1 with 92 trials, with the heaviest enrollment activity in Houston, New York, and Shanghai. Lead sponsors running malignancies studies include M.D. Anderson Cancer Center, National Cancer Institute (NCI), and UNC Lineberger Comprehensive Cancer Center.

Browse malignancies trials by phase

Treatments under study

About Malignancies Clinical Trials

Looking for clinical trials for Malignancies? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 182 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1Phase 2

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Hematologic MalignanciesHIV
National Cancer Institute (NCI)265 enrolled1 locationNCT05470491
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Myeloid Malignancies
M.D. Anderson Cancer Center42 enrolled1 locationNCT06930651
Recruiting
Phase 1Phase 2

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

PineoblastomaMedulloblastoma RecurrentEpendymoma Recurrent+3 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Hematologic Malignancies
M.D. Anderson Cancer Center35 enrolled1 locationNCT06807606
Recruiting

Pharmacogenetic Determinants Of Treatment Response In Children

All MalignanciesChildren Being Treated for Catastrophic Illness
St. Jude Children's Research Hospital8,800 enrolled1 locationNCT00730678
Recruiting
Phase 2

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.100 enrolled11 locationsNCT06665100
Recruiting
Not Applicable

Germline Testing for Predisposition to Myeloid Malignancies

Genetic Predisposition to DiseaseMyeloid MalignancyMyeloid Hematological Malignancies
Christopher Reilly200 enrolled1 locationNCT07112287
Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Solid Tumor MalignanciesCRC (Colorectal Cancer)KRAS G12C Mutation+1 more
Kumquat Biosciences Inc.140 enrolled11 locationsNCT06720987
Recruiting
Phase 2

IVIG for Infection Prevention After CAR-T-Cell Therapy

Hematologic Malignancies
Fred Hutchinson Cancer Center150 enrolled7 locationsNCT05952804
Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting
Phase 1Phase 2

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc310 enrolled5 locationsNCT07136779
Recruiting
Phase 1Phase 2

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc255 enrolled1 locationNCT07299747
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting
Phase 2

Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

Ovarian CancerSolid Tumor MalignanciesClear Cell Endometrial Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris900 enrolled4 locationsNCT07303387